このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Genmab マネジメント

マネジメント基準チェック /44

Genmab'sの CEO はJan van de Winkelで、 Jun2010年に任命され、の在任期間は 12.08年です。の年間総報酬はDKK 38.10Mで、 20.7%給与と79.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.94%を直接所有しており、その価値は€ 214.42M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と5.3年です。

主要情報

Jan van de Winkel

最高経営責任者

DKK 38.1m

報酬総額

CEO給与比率	20.7%
CEO在任期間	12.1yrs
CEOの所有権	0.9%
経営陣の平均在職期間	3.3yrs
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Genmab の収益と比較して、Jan van de Winkel の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2022	n/a	n/a	DKK 2b
Dec 31 2021	DKK 38m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 6b
Dec 31 2020	DKK 37m	DKK 7m	DKK 5b
Sep 30 2020	n/a	n/a	DKK 6b
Jun 30 2020	n/a	n/a	DKK 6b
Mar 31 2020	n/a	n/a	DKK 2b
Dec 31 2019	DKK 35m	DKK 7m	DKK 2b
Sep 30 2019	n/a	n/a	DKK 2b
Jun 30 2019	n/a	n/a	DKK 1b
Mar 31 2019	n/a	n/a	DKK 1b
Dec 31 2018	DKK 28m	DKK 7m	DKK 1b
Sep 30 2018	n/a	n/a	DKK 1b
Jun 30 2018	n/a	n/a	DKK 1b
Mar 31 2018	n/a	n/a	DKK 1b
Dec 31 2017	DKK 27m	DKK 7m	DKK 1b
Sep 30 2017	n/a	n/a	DKK 1b
Jun 30 2017	n/a	n/a	DKK 1b
Mar 31 2017	n/a	n/a	DKK 1b
Dec 31 2016	DKK 23m	DKK 6m	DKK 1b
Sep 30 2016	n/a	n/a	DKK 735m
Jun 30 2016	n/a	n/a	DKK 686m
Mar 31 2016	n/a	n/a	DKK 535m
Dec 31 2015	DKK 20m	DKK 5m	DKK 764m

報酬と市場: Janの総報酬 ($USD 5.18M ) は、 German市場 ($USD 5.03M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Janの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jan van de Winkel (61 yo)

12.1yrs

在職期間

DKK 38,100,000

報酬

Dr. Jan G. J. van de Winkel, Ph D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board.He is a Co-Founder of Genmab A/S...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jan van de Winkel	Co-Founder	12.1yrs	DKK 38.10m	0.94% DKK 214.4m
Anthony Pagano	Executive VP & CFO	2.3yrs	DKK 12.40m	0.0047% DKK 1.1m
Anthony Mancini	Executive VP & COO	2.3yrs	DKK 16.60m	データなし
Judith Klimovsky	Executive VP & Chief Development Officer	5.4yrs	DKK 19.80m	0.0080% DKK 1.8m
Tahamtan Ahmadi	Executive VP	1.3yrs	DKK 10.90m	0.0037% DKK 841.4k
Mijke Zachariasse	Director of Protein Production & Chemist and Non-Independent Director	no data	DKK 900.00k	0.00014% DKK 31.9k
Rima Nassar	VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director	no data	DKK 800.00k	0.0016% DKK 362.6k
Peter Ros	Senior Director of Finance & Accounting	no data	データなし	データなし
Andrew Carlsen	Senior Director	no data	データなし	データなし
Birgitte Stephensen	Executive VP & Chief Legal Officer	12.5yrs	データなし	データなし
Christopher Cozic	Executive VP & Chief People Officer	no data	データなし	データなし
Rachel Gravesen	Executive Officer	3.3yrs	データなし	データなし

3.3yrs

平均在職期間

52.5yo

平均年齢

経験豊富な経営陣: GE9の経営陣は経験豊富であると考えられます ( 3.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Mijke Zachariasse	Director of Protein Production & Chemist and Non-Independent Director	3.3yrs	DKK 900.00k	0.00014% DKK 31.9k
Rima Nassar	VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director	2.5yrs	DKK 800.00k	0.0016% DKK 362.6k
Anders Pedersen	Non-Independent Director	18.7yrs	DKK 1.40m	0.017% DKK 3.9m
Deirdre Connelly	Independent Chairman of the Board	5.3yrs	DKK 2.40m	0.0068% DKK 1.6m
Rolf Hoffmann	Independent Director	5.3yrs	DKK 1.40m	0.0045% DKK 1.0m
Pernille Erenbjerg	Independent Deputy Chairman	7.5yrs	DKK 1.80m	0.0066% DKK 1.5m
Paolo Paoletti	Independent Director	7.5yrs	DKK 1.30m	0.00093% DKK 212.1k
Elizabeth O'Farrell	Independent Director	less than a year	データなし	データなし

5.3yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: GE9の取締役会は経験豊富であると考えられます ( 5.3年の平均在任期間)。

Genmab マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Genmab A/S Announces Executive Changes

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

High number of new directors

Recent updates

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

High number of new directors

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44